PYXSPyxis Oncology, Inc.同业对比
Pyxis Oncology, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PYXS本股 | $280M#7 | — | 24.5x#10 | 20.2x#7 | -14.2%#9 | -3.0%#5 | -609.2%#7 | -696.0%#12 | — | — | 45.5%#5 | — |
| ABEO | $321M#1 | — | 2.5x#7 | 55.1x#8 | — | -211.7%#12 | -1536.9%#10 | -55.6%#7 | -121.6%#1 | — | -0.4%#9 | — |
| CTNM | $316M#2 | — | 1.3x#5 | — | -100.0%#12 | -41.9%#9 | — | -25.0%#4 | — | — | 10.2%#8 | — |
| VNDA | $307M#3 | — | 1.4x#6 | 1.4x#2 | 8.7%#7 | -1066.7%#15 | -70.0%#3 | -100.1%#9 | — | — | 12.5%#7 | — |
| CUE | $293M#4 | — | 126.7x#12 | 10.7x#6 | 195.7%#2 | 34.6%#2 | -96.7%#4 | -1151.6%#13 | — | — | 82.3%#2 | — |
| UPB | $292M#5 | — | 1.1x#2 | 102.5x#10 | 20.4%#6 | -128.4%#11 | -5618.8%#11 | -52.9%#6 | — | — | -69.0%#14 | — |
| FULC | $288M#6 | — | 0.9x#1 | — | -100.0%#12 | -670.0%#14 | — | -24.1%#3 | — | — | -49.9%#13 | — |
| GLSI | $275M#8 | — | 88.4x#11 | — | — | -11.2%#6 | — | -621.1%#11 | — | — | 62.9%#3 | — |
| TRDA | $268M#9 | — | 1.1x#4 | 10.6x#5 | -87.9%#11 | -319.0%#13 | -621.1%#8 | -61.6%#8 | — | — | 24.1%#6 | — |
| MGNX | $261M#10 | — | 6.1x#8 | 1.7x#3 | -0.3%#8 | -11.4%#7 | -48.7%#2 | -0.2%#1 | — | — | 137.4%#1 | — |
| LYEL | $260M#11 | — | 1.1x#3 | 7222.2x#11 | -41.0%#10 | 20.0%#3 | -748344.4%#12 | -117.4%#10 | — | — | -15.5%#10 | — |
| BCYC | — | — | — | — | 105.8%#3 | -29.5%#8 | -340.4%#6 | -42.9%#5 | -794.1%#2 | — | -48.8%#12 | — |
| CAMP | $253M#12 | — | — | 72.2x#9 | 436.5%#1 | -55.2%#10 | -1502.4%#9 | — | — | — | 60.0%#4 | — |
| AKBA | $247M#13 | — | 9.9x#9 | 1.0x#1 | 47.5%#4 | 92.4%#1 | 9.9%#1 | -21.2%#2 | — | — | -70.0%#15 | — |
| FHTX | $246M#14 | — | — | 8.0x#4 | 36.8%#5 | 14.2%#4 | -279.5%#5 | — | — | — | -19.6%#11 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议